Regulatory & market landscape
Amycretin arrived amid intense interest in the obesity market, and its novel design drew attention fast.
A drug the market is watching, not yet selling
Amycretin arrived amid intense interest in the obesity market, and its novel design drew attention fast. Yet no source this course uses records an approval anywhere, its phase 3 program is enrolling rather than reporting, and anything sold under its name as a "research peptide" is unverified.
This unit maps the regulatory reality, the transition from dose-finding to confirmatory trials, the athlete question, and the honest bottom-line verdict on a promising but still-unproven molecule. It also flags one naming trap: the molecule now carries the name zenagamtide, which its 2026 papers and releases use, and a search under only one name misses half the record.
Key terms
The regulatory status
The headline is simple: amycretin is not approved in the United States, and no source this course uses records an approval anywhere else. The openFDA label search returns no matches for the name, the labeling database returns zero documents, and the sponsor's own most recent release lists zenagamtide among medicines that are not approved in the United States. Novo Nordisk announced in June 2025 that both formulations would advance into phase 3 development in weight management, and the AMAZE program, registered under the development code NNC0487-0111 that the subcutaneous amycretin trial's registry record also uses, opened its first trial in February 2026. That is the start of the approval journey, not the end: a trial that is enrolling has proved nothing.
The anti-doping row below is read straight off WADA's own documents rather than off commentary. The 2026 Monitoring Program lists markers of semaglutide and tirzepatide, in- and out-of-competition, and the 2026 Prohibited List, which came into effect on 1 January 2026, contains neither amycretin nor zenagamtide anywhere in its text. Amycretin is named on neither document.
The regulatory picture is coherent: a novel drug with striking early data but no confirmatory evidence yet, now running the large trials approval requires. The dependence on a full phase 3 program is important; early-phase readouts, however eye-catching, do not make a filing.
AdvancedWhy phase 3 will take years
The registered phase 3 trials here are large and long: 1150 participants estimated for AMAZE 1 and 5610 for the heart-failure outcome trial, before follow-up, analysis and regulatory review. Amycretin also has two formulations, each with its own phase 3 registration, and its flagship obesity trial (AMAZE 1) measures its primary endpoint at week 84, with a primary completion date in 2029. Even on an aggressive timeline, that puts any possible approval years away, and every step could reshape the picture, including the possibility that the striking small-arm numbers do not hold up at scale.